Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $60.00 and last traded at $57.35, with a volume of 337658 shares changing hands. The stock had previously closed at $59.46.
Gemini Therapeutics Stock Performance
The company has a market capitalization of $2.71 billion, a price-to-earnings ratio of -57.35 and a beta of -0.12. The business has a 50-day simple moving average of $51.31 and a two-hundred day simple moving average of $45.31.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- Stock Market Upgrades: What Are They?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- The How and Why of Investing in Gold Stocks
- Williams-Sonoma Stock: Buy It and Never Let It Go
- How Technical Indicators Can Help You Find Oversold Stocks
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
